2024
Rates, Predictors, and Outcomes of Ustekinumab Dose Escalation in Inflammatory Bowel Disease.
Petrov J, Al-Bawardy B, Alzahrani R, Mohamed G, Fine S. Rates, Predictors, and Outcomes of Ustekinumab Dose Escalation in Inflammatory Bowel Disease. Journal Of Clinical Gastroenterology 2024 PMID: 38595134, DOI: 10.1097/mcg.0000000000002003.Peer-Reviewed Original ResearchUstekinumab dose escalationDose-escalation groupInflammatory bowel diseaseDose escalationC-reactive proteinEndoscopic healingEscalation groupClinical remissionNormalization of C-reactive proteinSteroid-free clinical remissionBowel diseaseSerum C-reactive proteinNormalization of serum C-reactive proteinMaintenance of remissionReal-world cohortProportion of patientsUstekinumab doseMean hemoglobinBaseline albuminRetrospective studyUstekinumabMale sexMultivariate analysisPrimary outcomeSecondary outcomesLonger Colonoscopy Withdrawal Time Is Associated With the Detection of Visible Dysplasia in Patients With Inflammatory Bowel Disease
McMillan C, Li D, Mohamed G, Alsadoun D, Almohsen L, Gaidos J, Proctor D, Al-Bawardy B. Longer Colonoscopy Withdrawal Time Is Associated With the Detection of Visible Dysplasia in Patients With Inflammatory Bowel Disease. Crohn's & Colitis 360 2024, 6: otae020. PMID: 38585555, PMCID: PMC10998460, DOI: 10.1093/crocol/otae020.Peer-Reviewed Original ResearchColonoscopy withdrawal timeHigh-definition white light colonoscopyInflammatory bowel diseaseWhite light colonoscopyVisible dysplasiaBowel diseasePersonal historyWithdrawal timeAssociated with detectionEndoscopic healingAdenoma detectionDysplasia detectionDysplasia groupRetrospective studyAdult patientsInvisible dysplasiaColonoscopyPrimary outcomeDysplasiaMultivariate analysisPatientsIncreasing ageGeneral populationMinutesDiseaseUstekinumab Drug Levels and Outcomes in Inflammatory Bowel Disease.
Petrov J, Fine S, Alzahrani R, Mohamed G, Al-Bawardy B. Ustekinumab Drug Levels and Outcomes in Inflammatory Bowel Disease. Journal Of Clinical Gastroenterology 2024 PMID: 38300529, DOI: 10.1097/mcg.0000000000001978.Peer-Reviewed Original ResearchArea under the curveInflammatory bowel diseaseEndoscopic healingTrough levelsBowel diseaseAssociated with favorable outcomesUstekinumab trough levelsHighest area under the curveCohort of patientsTherapeutic drug monitoringClinical remissionCombination therapyMedian ageCRP normalizationRetrospective studyDrug levelsFavorable outcomeUstekinumabDrug monitoringPrimary outcomeSecondary outcomesCRPPatientsOutcomesHealing
2023
Early Flexible Sigmoidoscopy Improves Clinical Outcomes in Acute Severe Ulcerative Colitis
Sharma S, Li D, Levine L, Chaar A, McMillan C, Gaidos J, Proctor D, Al-Bawardy B. Early Flexible Sigmoidoscopy Improves Clinical Outcomes in Acute Severe Ulcerative Colitis. Crohn's & Colitis 360 2023, 5: otad032. PMID: 37323477, PMCID: PMC10263117, DOI: 10.1093/crocol/otad032.Peer-Reviewed Original ResearchAcute severe ulcerative colitisSevere ulcerative colitisClinical outcomesSigmoidoscopy groupHospital stayFlexible sigmoidoscopyUlcerative colitisIntravenous corticosteroid useRate of colectomyRisk of colectomyHours of admissionOpioid medication useShorter hospital stayCohort of patientsFavorable clinical outcomeLarge prospective studiesRelevant clinical outcomesColectomy rateCorticosteroid useSecondary outcomesMedication usePrimary outcomeProspective studyRetrospective studySigmoidoscopyOutcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease
Sayed A, Assis D, Silveira M, Deng Y, Ciarleglio M, Gaidos J, Proctor D, Al-Bawardy B. Outcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease. European Journal Of Gastroenterology & Hepatology 2023, 35: 270-274. PMID: 36708297, DOI: 10.1097/meg.0000000000002510.Peer-Reviewed Original ResearchConceptsPrimary sclerosing cholangitisInflammatory bowel diseasePSC-IBDEndoscopic healingTherapy groupAdvanced therapiesClinical remissionBowel diseaseAcute ascending cholangitisRate of cholangitisSmall bowel involvementThird of patientsAscending cholangitisSclerosing cholangitisAdult patientsBowel involvementSecondary outcomesMedian agePrimary outcomeRetrospective studyHigh riskCholangitisPatientsTherapyLarger study
2021
The Impact of Inflammatory Bowel Disease Clinic On-site Vaccination Services
Hussain N, Proctor D, Al-Bawardy B. The Impact of Inflammatory Bowel Disease Clinic On-site Vaccination Services. Crohn's & Colitis 360 2021, 3: otab067. PMID: 36777277, PMCID: PMC9802036, DOI: 10.1093/crocol/otab067.Peer-Reviewed Original ResearchInflammatory bowel diseaseClinic BIBD clinicHerpes zosterClinic AVaccination servicesSite vaccinationVaccine discussionsInflammatory bowel disease clinicHepatitis B vaccinationVaccine-preventable diseasesLow vaccination ratesCompletion ratesB vaccinationIBD patientsIBD physiciansVaccine completionBowel diseaseDisease clinicClinic 1Retrospective studyVaccination ratesDiscussion rateComprehensive careImmunization rates
2020
The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study
Ramos GP, Dimopoulos C, McDonald NM, Janssens LP, Hung KW, Proctor D, Ruggiero E, Kane S, Bruining DH, Faubion WA, Raffals LE, Loftus EV, Al-Bawardy B. The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study. Inflammatory Bowel Diseases 2020, 27: 1270-1276. PMID: 33165569, DOI: 10.1093/ibd/izaa293.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseExtraintestinal manifestationsPeripheral arthritisBowel diseaseDose of vedolizumabPrevious biologic useMulticenter retrospective studyCurrent medical therapyTerms of ageConcurrent immunosuppressantsCorticosteroid therapyVDZ treatmentIBD subtypesBiologic useSecondary outcomesMedical therapyPrimary outcomeClinical outcomesMulticenter studyRetrospective studyVedolizumabPatientsCommon typeDiscontinuationArthritis
2017
Cross-sectional imaging in refractory celiac disease
Al-Bawardy B, Barlow JM, Vasconcelos RN, Kim ST, Bruining DH, Hansel SL, Sheedy SP, Murray JA, Rubio-Tapia A, Rajan E, Fidler JL, Fletcher JG. Cross-sectional imaging in refractory celiac disease. Abdominal Radiology 2017, 42: 389-395. PMID: 28084545, DOI: 10.1007/s00261-016-1032-0.Peer-Reviewed Original ResearchConceptsType II refractory celiac diseaseRefractory celiac diseaseCross-sectional imagingCeliac diseaseUlcerative jejunitisSB dilationSmall bowelResultsOne hundred eighteen patientsPattern abnormalitiesT-cell receptor rearrangementsUnique imaging findingsCell receptor rearrangementNon-significant trendType IDuodenal edemaJejunal foldsRefractory symptomsEighteen patientsMesenteric lymphadenopathyImaging findingsRetrospective studyRCD patientsType IIBlinded reviewPatientsCollagenous sprue cross-sectional imaging: a comparative blinded study
Al-Bawardy B, Sheedy SP, Herberts MB, Murray JA, Rubio-Tapia A, Rajan E, Bruining DH, Hansel SL, Barlow JM, Fletcher JG, Fidler JL. Collagenous sprue cross-sectional imaging: a comparative blinded study. Abdominal Radiology 2017, 42: 396-402. PMID: 28058450, DOI: 10.1007/s00261-016-1007-1.Peer-Reviewed Original ResearchConceptsCT enterographyCS patientsIBS groupCross-sectional imaging findingsIrritable bowel syndrome patientsAngiotensin receptor blockersSmall bowel biopsyAbdomen/pelvisBowel syndrome patientsMagnetic resonance enterographySubepithelial collagen bandBowel biopsyMucosal malabsorptionRare enteropathySB dilationUlcerative jejunoileitisReceptor blockersVillous atrophyResonance enterographyImaging findingsRetrospective studyMean ageControl subjectsHistopathologic diagnosisInclusion criteria